Posted innews
专用于原发性主动脉瓣反流的TAVI：ALIGN-AR显示2年内的可行安全性和持久效果
ALIGN-AR项目表明，Trilogy经导管心脏瓣膜在高风险原发性主动脉瓣反流患者中具有较高的技术成功率、可接受的30天安全性、低残余反流率以及良好的1年和2年死亡率。
Posted inDiabetes & Endocrinology news
Orforglipron in Type 2 Diabetes and Obesity: A Promising Oral GLP‑1 Agonist That Delivers Clinically Meaningful Weight and Glycaemic Benefits
In ATTAIN‑2, oral orforglipron produced dose‑dependent, statistically superior weight loss and improved HbA1c versus placebo over 72 weeks in adults with overweight/obesity and type 2 diabetes, with an adverse‑event profile dominated by gastrointestinal effects.
Posted inAnesthesiology Emergency Medicine news
Inhaled Methoxyflurane Matches or Exceeds Standard Analgesics for Rapid Prehospital Pain Relief: Results from the PreMeFen Randomised Trial
The PreMeFen trial found inhalational methoxyflurane provided rapid, clinically meaningful pain relief at 10 minutes and was non-inferior to intranasal fentanyl and intravenous morphine in the prehospital setting, offering a practical non‑intravenous bridging option.
Posted inDiabetes & Endocrinology Nephrology news
Balcinrenone plus Dapagliflozin Reduces Albuminuria in CKD: MIRO‑CKD Phase 2b Shows Dose‑Dependent Benefit with Acceptable Safety
The MIRO‑CKD phase 2b trial found that adding the non‑steroidal MRA balcinrenone to dapagliflozin reduced albuminuria versus dapagliflozin alone in people with CKD, with dose‑dependent effects and modest hyperkalaemia rates over 12 weeks.
Posted innews Rheumatology
FcRn blockade with nipocalimab reduces disease activity in moderate‑to‑severe Sjögren’s syndrome: positive phase 2 DAHLIAS results
In DAHLIAS, intravenous nipocalimab 15 mg/kg every 2 weeks for 22 weeks significantly reduced ClinESSDAI scores versus placebo in anti‑Ro seropositive patients with moderate‑to‑severe Sjögren’s disease, with a safety profile similar to placebo.
Posted inDermatology Hematology-Oncology news
JAK2 Gene Fusions in Adult Patients with Mycosis Fungoides and CD30-Positive Lymphoproliferative Disorders: A Case Series
This case series highlights the presence and clinical significance of JAK2 gene fusions across a spectrum of cutaneous T-cell lymphomas, including indolent and aggressive presentations.
Posted inDermatology news
Standardizing How Clinicians See Hidradenitis Suppurativa: Key Consensus on Lesion Definitions and Investigator Guidance from a Modified Delphi Exercise
An international Delphi consensus produced standardized morphological definitions and practical guidance to improve investigator lesion assessment in hidradenitis suppurativa clinical trials, enhancing reliability and trial data quality.
Posted innews Ophthalmology Otorhinolaryngology
Clinical Findings and Molecular Genetics of USH1C-Associated Usher Syndrome: A Retrospective Case Series
This case series reviews clinical features, genetic variants, visual outcomes, and psychosocial impact in 28 patients with USH1C-associated Usher syndrome, highlighting slow retinal degeneration and significant social burden.
Posted inDermatology news
Standardizing How Investigators Identify Hidradenitis Suppurativa Lesions: Key Findings from a Modified Delphi Consensus
A multidisciplinary Delphi panel produced consensus morphological definitions and practical guidance to standardize investigator lesion assessments in hidradenitis suppurativa (HS) clinical trials — improving reliability of endpoints such as HiSCR and IHS4.
Posted innews Oncology Orthopedics Otorhinolaryngology Radiology
Higher Osteoradionecrosis Risk After Proton Therapy than IMRT in Oropharyngeal Cancer — What Clinicians Should Know
In a large single‑institution cohort of oropharyngeal squamous cell carcinoma, proton therapy was associated with a higher 3‑year rate of osteoradionecrosis than IMRT (6.4% vs 2.7%), though severe ORN remained uncommon.
Posted inHematology-Oncology news Oncology
Hidden Burden: Nearly 1 in 10 Adolescents and Young Adults Develop Metastatic Recurrence — Survival Often Worse Than De Novo Metastasis
A California cohort study found a 5-year cumulative incidence of metastatic recurrence of 9.5% among adolescents and young adults (AYAs) initially diagnosed with nonmetastatic cancer; recurrence risk and post-recurrence survival varied markedly by tumor type and stage.
Posted innews Otorhinolaryngology
Engasertib Shows Promise for Reducing Epistaxis in HHT but Benefits Are Modest — Safety Profile Acceptable in Short Term
A randomized, double-blind placebo-controlled proof-of-concept trial of engasertib (AKT inhibitor) in hereditary hemorrhagic telangiectasia showed modest reductions in epistaxis frequency and duration versus placebo and a tolerable safety profile over 12 weeks; larger, longer trials are needed.
Posted inInfectious Diseases news Public Health
Daily High‑Dose Mosnodenvir Significantly Lowers DENV‑3 Viremia in a Human Challenge — Proof‑of‑Concept with Early Resistance Signals
In a phase 2a human challenge, high‑dose daily mosnodenvir substantially reduced DENV‑3 RNA burden versus placebo without serious adverse events, but treatment‑associated NS4B viral mutations emerged, highlighting efficacy and resistance concerns that require larger field studies.
Posted inHematology-Oncology news Otorhinolaryngology
Engasertib Shows Promise for Recurrent Epistaxis in HHT: Proof‑of‑Concept Trial Demonstrates Reduced Bleeding with Acceptable Short‑Term Safety
In a randomized, double‑blind, placebo‑controlled proof‑of‑concept trial, oral engasertib reduced epistaxis frequency and duration in hereditary hemorrhagic telangiectasia (HHT) with a safety profile similar to placebo except for reversible rash and occasional hyperglycemia.
Posted inHematology-Oncology Infectious Diseases news
A viral clonality evenness score accurately identifies HTLV‑1 carriers at high risk of adult T‑cell leukaemia
A clonality evenness score (VCE) derived from HTLV‑1 integration sequencing discriminates asymptomatic carriers who later develop adult T‑cell leukaemia from those who do not, outperforming proviral load alone in individual-level prediction in a Japanese longitudinal cohort.
Posted inCritical Care Nephrology news
Biomarker-Guided Preventive Care Halves Risk of Moderate–Severe AKI After Major Surgery: Results from BigpAK-2
In BigpAK-2, a multinational randomized trial, a KDIGO-based preventive bundle triggered by tubular stress biomarkers reduced moderate or severe acute kidney injury within 72 hours after major surgery (OR 0.57; NNT 12) without increasing adverse events.
Posted innews
PLCOm2012 风险分层选择优于 NELSON 标准用于德国肺癌检测：HANSE 队列研究结果
在 HANSE 研究中，PLCOm2012（6 年风险 ≥1.58%）选择了更多的肺癌病例，并且筛查所需的样本数量低于 NELSON 标准，支持在 CT 筛查项目中使用风险模型选择，但需注意其普遍性和死亡率终点的局限性。
Posted innews Oncology Respiratory
PLCOm2012 Risk-Based Selection Outperforms NELSON Criteria for Lung Cancer Detection in Germany: Findings from the HANSE Cohort
In HANSE, PLCOm2012 (6‑year risk ≥1.58%) selected more lung cancers and yielded a lower number needed to screen than NELSON criteria, supporting risk-model selection for CT screening programs, with caveats on generalisability and mortality endpoints.
Posted inHematology-Oncology news
Ropeginterferon alfa-2b Superior to Anagrelide as Second-line Therapy in Hydroxyurea‑Intolerant or ‑Refractory Essential Thrombocythaemia: SURPASS‑ET Phase 3 Results
SURPASS‑ET, a phase 3 randomized trial, showed ropeginterferon alfa‑2b achieved durable ELN responses in 43% of hydroxyurea‑intolerant/refractory ET patients with leukocytosis versus 6% with anagrelide, with a favorable safety profile and fewer serious adverse events.
Posted innews Rheumatology
Whole‑Genome Sequencing Reveals HLA, FCGR2B and Complement C4 Copy‑Number as Distinct Genetic Drivers of IgG4‑Related Disease in Japan
A Japanese whole‑genome sequencing study identifies FCGR2B, specific HLA amino‑acid residues, and complement C4 copy‑number variation as independent genetic risk factors for IgG4‑related disease, with PTCH1 and a lncRNA linked to Mikulicz’s disease.
